Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

CD133 expression in chemo-resistant Ewing sarcoma cells.

Jiang X, Gwye Y, Russell D, Cao C, Douglas D, Hung L, Kovar H, Triche TJ, Lawlor ER.

BMC Cancer. 2010 Mar 26;10:116. doi: 10.1186/1471-2407-10-116.

2.

ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.

Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.

PLoS One. 2011;6(6):e20636. doi: 10.1371/journal.pone.0020636. Epub 2011 Jun 13.

3.

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.

Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR.

Reprod Biol Endocrinol. 2010 Dec 1;8:147. doi: 10.1186/1477-7827-8-147.

4.

CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.

Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R.

Stem Cells. 2009 Dec;27(12):2875-83. doi: 10.1002/stem.236.

5.

Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells.

Zhou J, Wang H, Cannon V, Wolcott KM, Song H, Yates C.

Mol Cancer. 2011 Sep 14;10:112. doi: 10.1186/1476-4598-10-112.

6.

Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy.

Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, Ichihara E, Yamane H, Tanimoto M, Kiura K.

Cancer Sci. 2013 Jan;104(1):78-84. doi: 10.1111/cas.12045. Epub 2012 Nov 24.

7.

Biological and genetic characteristics of tumor-initiating cells in colon cancer.

Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, Matsumoto T, Inoue H, Kuwano H, Mori M.

Ann Surg Oncol. 2008 Feb;15(2):638-48. Epub 2007 Oct 12.

PMID:
17932721
8.

Prominin 1/CD133 endothelium sustains growth of proneural glioma.

Ding BS, James D, Iyer R, Falciatori I, Hambardzumyan D, Wang S, Butler JM, Rabbany SY, Hormigo A.

PLoS One. 2013 Apr 25;8(4):e62150. doi: 10.1371/journal.pone.0062150. Print 2013.

9.

CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Müllerian tumor).

Choijamts B, Jimi S, Kondo T, Naganuma Y, Matsumoto T, Kuroki M, Iwasaki H, Emoto M.

Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.

10.

Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.

Ma HI, Chiou SH, Hueng DY, Tai LK, Huang PI, Kao CL, Chen YW, Sytwu HK.

J Neurosurg. 2011 Mar;114(3):651-62. doi: 10.3171/2009.11.JNS091396. Epub 2010 Nov 5.

PMID:
21054139
11.

CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.

Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R.

Cancer Biol Ther. 2010 Dec 1;10(11):1182-90. Epub 2010 Dec 1.

PMID:
20948317
12.

Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.

Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL.

J Neurooncol. 2009 Aug;94(1):1-19. doi: 10.1007/s11060-009-9919-z. Epub 2009 May 26.

13.

CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.

Dittfeld C, Dietrich A, Peickert S, Hering S, Baumann M, Grade M, Ried T, Kunz-Schughart LA.

Radiother Oncol. 2009 Sep;92(3):353-61. doi: 10.1016/j.radonc.2009.06.034. Epub 2009 Aug 21.

PMID:
19699546
14.

Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.

Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G.

Clin Cancer Res. 2009 Jul 1;15(13):4299-311. doi: 10.1158/1078-0432.CCR-08-1883. Epub 2009 Jun 9.

15.

Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine.

Snippert HJ, van Es JH, van den Born M, Begthel H, Stange DE, Barker N, Clevers H.

Gastroenterology. 2009 Jun;136(7):2187-2194.e1. doi: 10.1053/j.gastro.2009.03.002. Epub 2009 Mar 24.

PMID:
19324043
16.

Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas.

Holmberg Olausson K, Maire CL, Haidar S, Ling J, Learner E, Nistér M, Ligon KL.

PLoS One. 2014 Sep 3;9(9):e106694. doi: 10.1371/journal.pone.0106694. eCollection 2014.

17.

[Sorting of CD133(+) subset cells in human gastric cancer and the identification of their tumor initiating cell-like properties].

Lu RQ, Wu JG, Zhou GC, Jiang HG, Yu JW, Jiang BJ.

Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Feb;15(2):174-9. Chinese.

PMID:
22368028
18.

Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents.

Vangipuram SD, Wang ZJ, Lyman WD.

Pediatr Blood Cancer. 2010 Mar;54(3):361-8. doi: 10.1002/pbc.22351.

19.

Identification and metastatic potential of tumor-initiating cells in malignant rhabdoid tumor of the kidney.

Yanagisawa S, Kadouchi I, Yokomori K, Hirose M, Hakozaki M, Hojo H, Maeda K, Kobayashi E, Murakami T.

Clin Cancer Res. 2009 May 1;15(9):3014-22. doi: 10.1158/1078-0432.CCR-08-2237. Epub 2009 Apr 21.

20.

A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.

Liu XJ, Wu WT, Wu WH, Yin F, Ma SH, Qin JZ, Liu XX, Liu YN, Zhang XY, Li P, Han S, Liu KY, Zhang JM, He QH, Shen L.

CNS Neurosci Ther. 2013 Jul;19(7):494-502. doi: 10.1111/cns.12092. Epub 2013 Apr 10.

PMID:
23575351

Supplemental Content

Support Center